Strategic Initiative

Slingshot members are tracking this corporate initiative:

Juno Therapeutics Signs Licensing Agreement with Lilly to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details “We plan to begin clinical trials in 2018 combining a gamma secretase inhibitor with our BCMA CAR T product candidates.”Through its agreement with Eli Lilly and Company, Juno will acquire a license to the GSI known as LY3039478, a product candidate that has been studied in 411 patients and healthy volunteers. Through its agreements with OncoTracker and Fred Hutchinson Cancer Research Center, Juno will gain exclusive rights to intellectual property within the field of combinations of GSIs and BCMA-directed engineered T cells.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Dec 06, 2017
Projected Implementation:
Q1, 2018
Relevance Tracked Until:
Q3, 2018
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords T-cell Therapy, Multiple Myeloma